{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:36:20Z","timestamp":1791387380674,"version":"4.3.3"},"reference-count":33,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Belgian Fonds National de la Recherche Scientifique","award":["40011958"],"award-info":[{"award-number":["40011958"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Menopause is thought to have beneficial effects in women with prolactinoma, potentially offering a higher chance for successful dopamine agonist (DA) withdrawal. However, strong evidence supporting this remains limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the impact of menopause on prolactinoma evolution and recurrence after DA withdrawal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Two tertiary academic hospitals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>We retrospectively analyzed data from 99 women undergoing menopause (Mp, defined as 12 months of amenorrhea, low estradiol, and FSH &amp;gt; 25\u2005U\/L) while still on DA treatment for a prolactinoma (mean age at diagnosis: 37.9 \u00b1 8.1 years). The tumors were microadenomas in 67 cases and macroadenomas in 32 (12 invasive).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In postmenopausal women continuing DA at stable doses, median prolactin levels decreased significantly from 18.0\u2005\u00b5g\/L before Mp to 9.8\u2005\u00b5g\/L 3 to 6 months after Mp (n = 71, P = .05) and to 7.9\u2005\u00b5g\/L after 24 months (n = 45, P &amp;lt; .001). Coronal surface also decreased significantly from 16.5 to 8.2\u2005mm\u00b2 at 24 months (n = 34, P &amp;lt; .01). DA treatment was successfully discontinued in 56 women, all meeting stringent criteria for discontinuation, with 41 (73%) remaining in remission over a median follow-up of 29 months. Recurrence occurred in 15 women (27%), mostly within the first year after DA withdrawal. Prolactin concentration measured 3 to 6 months after DA discontinuation was the only independent predictor of recurrence. Estrogen-progestin replacement therapy, given in 23 women, did not influence prolactinoma outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We confirm that menopause has a beneficial effect on the evolution of prolactinomas. When fulfilling stringent criteria for DA withdrawal, two-thirds of postmenopausal women can expect sustained remission, and recurrences are generally mild and asymptomatic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf152","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:21:20Z","timestamp":1741188080000},"page":"e3701-e3708","source":"Crossref","is-referenced-by-count":10,"title":["Menopause Has a Beneficial Influence on the Evolution of Prolactinomas. A Study of 99 Patients"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-9455","authenticated-orcid":false,"given":"Stefan Matei","family":"Constantinescu","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc , Brussels 1200 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina Maria","family":"Nava","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc , Brussels 1200 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Chasseloup","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction et Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse HYPO , Le Kremlin-Bic\u00eatre 94270 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsalia","family":"Alexopoulou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc , Brussels 1200 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction et Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse HYPO , Le Kremlin-Bic\u00eatre 94270 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-637X","authenticated-orcid":false,"given":"Dominique","family":"Maiter","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc , Brussels 1200 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"issue":"12","key":"2025101519585522400_dgaf152-B1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2025101519585522400_dgaf152-B2","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2025101519585522400_dgaf152-B3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"2025101519585522400_dgaf152-B4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11102-019-00989-1","article-title":"Dopamine agonists in prolactinomas: when to withdraw?","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"issue":"2","key":"2025101519585522400_dgaf152-B5","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1210\/clinem\/dgaa744","article-title":"Biochemical remission after cabergoline withdrawal in hyperprolactinemic patients with visible remnant pituitary adenoma","volume":"106","author":"Kim","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025101519585522400_dgaf152-B6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/cen.14714","article-title":"Withdrawal of dopamine agonist treatment in patients with hyperprolactinaemia: a systematic review and meta-analysis","volume":"97","author":"Andersen","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2025101519585522400_dgaf152-B7","doi-asserted-by":"crossref","first-page":"e4558","DOI":"10.1210\/clinem\/dgaa652","article-title":"Predictors of the response to dopaminergic therapy in patients with prolactinoma","volume":"105","author":"Hage","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025101519585522400_dgaf152-B8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11102-019-00998-0","article-title":"Prolactinomas and menopause: any changes in management?","volume":"23","author":"Greenman","year":"2020","journal-title":"Pituitary"},{"issue":"2","key":"2025101519585522400_dgaf152-B9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/GME.0000000000002303","article-title":"Prolactinoma in postmenopausal women: a systematic review","volume":"31","author":"Carneiro","year":"2024","journal-title":"Menopause"},{"issue":"3","key":"2025101519585522400_dgaf152-B10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025101519585522400_dgaf152-B11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1590\/2359-3997000000138","article-title":"Prolactinomas: evolution after menopause","volume":"60","author":"Mallea-Gil","year":"2016","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"2025101519585522400_dgaf152-B12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.13765","article-title":"Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal","volume":"89","author":"Santharam","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2-3","key":"2025101519585522400_dgaf152-B13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12672-019-00363-4","article-title":"Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas","volume":"10","author":"Indirli","year":"2019","journal-title":"Horm Cancer"},{"issue":"4","key":"2025101519585522400_dgaf152-B14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1210\/jc.2011-3362","article-title":"Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging","volume":"97","author":"Harlow","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025101519585522400_dgaf152-B15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1210\/js.2019-00130","article-title":"Comparison of radiographic approaches to assess treatment response in pituitary adenomas: is RECIST or RANO good enough?","volume":"3","author":"Imber","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025101519585522400_dgaf152-B16","unstructured":"Constantinescu SM, Nava C, Chasseloup F \u00a0et al \u00a0Data from: Supplemental file from \u201cMenopause has a beneficial influence on the evolution of prolactinomas. A study of 99 patients\u201d. Figshare. 10.6084\/m9.figshare.28218635."},{"key":"2025101519585522400_dgaf152-B17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/B978-0-323-99899-4.00011-1","volume-title":"The Pituitary Fifth ed","author":"Chanson","year":"2022"},{"issue":"7","key":"2025101519585522400_dgaf152-B18","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025101519585522400_dgaf152-B19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s11102-017-0820-z","article-title":"Best candidates for dopamine agonist withdrawal in patients with prolactinomas","volume":"20","author":"Ji","year":"2017","journal-title":"Pituitary"},{"issue":"11","key":"2025101519585522400_dgaf152-B20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/BF03348037","article-title":"Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia","volume":"21","author":"Touraine","year":"1998","journal-title":"J Endocrinol Invest"},{"issue":"18","key":"2025101519585522400_dgaf152-B21","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.7150\/ijms.51176","article-title":"Estrogen receptor alpha\/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas","volume":"17","author":"Xiao","year":"2020","journal-title":"Int J Med Sci"},{"key":"2025101519585522400_dgaf152-B22","doi-asserted-by":"crossref","first-page":"791633","DOI":"10.3389\/fendo.2021.791633","article-title":"Resistance to dopamine agonists in pituitary tumors: molecular mechanisms","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2025101519585522400_dgaf152-B23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02899695","article-title":"Pituitary lactotrophs and somatotrophs in pregnancy: a correlative in situ hybridization and immunocytochemical study","volume":"62","author":"Stefaneanu","year":"1992","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"issue":"2","key":"2025101519585522400_dgaf152-B24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2265.1986.tb00754.x","article-title":"Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women","volume":"24","author":"Hwang","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025101519585522400_dgaf152-B25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/09513599709152546","article-title":"Changes in prolactin levels with the menopause: the effects of estrogen\/androgen and calcitonin treatment","volume":"11","author":"Balint-Peric","year":"1997","journal-title":"Gynecol Endocrinol"},{"issue":"12","key":"2025101519585522400_dgaf152-B26","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1073\/pnas.75.12.5946","article-title":"Estrogen control of prolactin synthesis in vitro","volume":"75","author":"Lieberman","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2025101519585522400_dgaf152-B27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0065-1281(97)80022-0","article-title":"Heterogeneity of pituitary lactotrophs: immunocytochemical identification of functional subtypes","volume":"99","author":"De Paul","year":"1997","journal-title":"Acta Histochem"},{"issue":"6","key":"2025101519585522400_dgaf152-B28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025101519585522400_dgaf152-B29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","article-title":"Women with prolactinomas presented at the postmenopausal period","volume":"47","author":"Shimon","year":"2014","journal-title":"Endocrine"},{"issue":"5","key":"2025101519585522400_dgaf152-B30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cen.13399","article-title":"Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes","volume":"87","author":"Santharam","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025101519585522400_dgaf152-B31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"},{"issue":"3","key":"2025101519585522400_dgaf152-B32","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2003-0965","article-title":"Folliculostellate cells determine the susceptibility of lactotropes to estradiol's mitogenic action","volume":"145","author":"Oomizu","year":"2004","journal-title":"Endocrinology"},{"issue":"3","key":"2025101519585522400_dgaf152-B33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/endo-112-3-813","article-title":"Evidence for paracrine interaction between gonadotrophs and lactotrophs in pituitary cell aggregates","volume":"112","author":"Denef","year":"1983","journal-title":"Endocrinology"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf152\/62310604\/dgaf152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf152\/62310604\/dgaf152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf152\/62310604\/dgaf152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:59:07Z","timestamp":1760572747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/11\/e3701\/8058932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,3,7]]},"published-print":{"date-parts":[[2025,10,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf152","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,3,7]]}}}